AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Managing Immune-Related Adverse Events of Checkpoint Inhibitors
The chapter delves into the complexities of treating immune-related adverse events (IRA-Es) caused by combination therapies like CTLA4 and PD-1 or PDL1 inhibitors, emphasizing the need for a multidisciplinary approach involving oncologists and rheumatologists. It discusses the model adopted at Hopkins for handling IRAEs, highlighting a dedicated team of specialists collaborating with oncologists. The setup in the clinic to manage these adverse events is detailed, focusing on specialized equipment and refining systems for improved patient care.